Immunome to acquire AL102 Phase 3 desmoid tumor asset from Ayala for $20M cash + $30M stock

Immunome Inc.

Immunome will acquire AL102 and AL101 from Ayala for $20M cash and ~$30M in stock (2.18M shares).
Up to $37.5M in development and commercial milestone payments; closing requires Ayala stockholder approval.
AL102 is a gamma secretase inhibitor in a Phase 3 trial for desmoid tumors; Phase 2 data showed 75% ORR.
AL102 granted FDA Orphan Drug Designation in Nov 2023; desmoid tumors affect ~1,650 diagnosed annually in U.S.
Transaction to complement Immunome's targeted cancer pipeline; Ayala's stock trades OTCQX under ADXS.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immunome Inc. entered into Asset Purchase Agreement with Ayala Pharmaceuticals, Inc. valued at $20,000,000 (effective 2024-02-05).

Action: entry
Agreement: asset purchase
Counterparty: Ayala Pharmaceuticals, Inc.
Value: $20,000,000
Effective: 2024-02-05

Exact text from the filing

On February 5, 2024, Immunome, Inc. (the “Company”) and Ayala Pharmaceuticals, Inc. (“Ayala”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company will acquire Ayala’s AL101 and AL102 programs and assume certain of Ayala’s liabilities associated with the acquired assets

View on SEC.gov

154 material agreements filed in the last 30 days. Browse all material agreements →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-010945

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.